Peptide bfp4 for promoting osteogenesis or vascularization and use thereof

Abstract

Disclosed are a peptide for promoting osteogenesis and vascularization, and the use thereof. The peptide has a low molecular weight so that it can be economically produced. In addition, it promotes osteoblastic differentiation, thus inducing osteogenesis. Further, the peptide can promote the expression of VEGF, resulting in vascularization. Accordingly, the peptide is useful for the prophylaxis or therapy of ischemic diseases.

1 . A peptide for promoting osteogenesis or vascularization, comprising an amino acid sequence of SEQ ID NO: 1. 
     
     
         2 . The peptide of  claim 1 , wherein the amino acid sequence of SEQ ID NO: 1 is derived from BMP7. 
     
     
         3 . The peptide of  claim 1 , having an activity of promoting osteoblastic differentiation or Vascular endothelial growth factor expression. 
     
     
         4 . The peptide of  claim 1 , having an activity of promoting osteogenesis and vascularization. 
     
     
         5 . The peptide of  claim 1 , wherein the peptide is an isolated peptide. 
     
     
         6 . The peptide of  claim 1 , wherein the peptide is an isolated and substantially purified peptide. 
     
     
         7 . An isolated polynucleotide, encoding the peptide of  claim 1 . 
     
     
         8 . A recombinant vector, carrying the polynucleotide of  claim 7 . 
     
     
         9 . A pharmaceutical composition for prophylaxis or therapy of a bone disease or an ischemic disease, comprising as an active ingredient the peptide of  claim 1 , a polynucleotide encoding the peptide, a recombinant vector carrying the polynucleotide, or a combination thereof. 
     
     
         10 . The pharmaceutical composition of  claim 9 , wherein the bone disease is selected from the group consisting of osteoporosis, osteoarthritis, bone fracture, osteoporosis imperfect and a combination thereof. 
     
     
         11 . The pharmaceutical composition of  claim 9 , wherein the ischemic disease is selected from the group consisting of ischemic necrosis, ischemic cerebrovascular disease, ischemic renal diseases, ischemic lung diseases, ischemic diseases of limbs, ischemic heart diseases, apoplexy, cerebral infarction, myocardial infarction, ischemic heart failure, obstructive arteriosclerosis, and a combination thereof. 
     
     
         12 . A method of preventing or treating a disease selected from the group consisting of a bone disease, an ischemic disease and a combination thereof, the method comprising:
 administering a subject with a therapeutically or pharmaceutically effective amount of a peptide comprising an amino acid sequence of SEQ ID NO: 1.   
     
     
         13 . The method of  claim 12 , wherein the disease is the bone disease. 
     
     
         14 . The pharmaceutical composition of  claim 13 , wherein the bone disease is selected from the group consisting of osteoporosis, osteoarthritis, bone fracture, osteoporosis imperfect and a combination thereof. 
     
     
         15 . The method of  claim 12 , wherein the disease is the ischemic disease. 
     
     
         16 . The pharmaceutical composition of  claim 15 , wherein the ischemic disease is selected from the group consisting of ischemic necrosis, ischemic cerebrovascular disease, ischemic renal diseases, ischemic lung diseases, ischemic diseases of limbs, ischemic heart diseases, apoplexy, cerebral infarction, myocardial infarction, ischemic heart failure, obstructive arteriosclerosis, and a combination thereof. 
     
     
         17 . The method of  claim 12 , wherein the subject is a human.